Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma

Lipika Goyal(Massachusetts General Hospital), John Bridgewater(University College Hospital), Karim A. Benhadji(Dana-Farber Cancer Institute), Volker Wacheck(Medical University of Vienna), Robert S. Epstein(Dana-Farber Cancer Institute), Markus Moehler(Johannes Gutenberg University Mainz), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya), Robin Kate Kelley(University of California, San Francisco), Thomas B. Karasic(Hospital of the University of Pennsylvania), Philippe A. Cassier(Lyon College), Tehseen Salimi(Dana-Farber Cancer Institute), Thomas A. Abrams(Dana-Farber Cancer Institute), Heinz‐Josef Klümpen(Amsterdam University Medical Centers), Yoshito Komatsu(Hokkaido University Hospital), Junji Furuse(Kyorin University), Do‐Youn Oh(Seoul National University), Yao Fu(Illumina (United States)), Daniel H. Ahn(Mayo Clinic Hospital), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Juan W. Valle(The Christie NHS Foundation Trust), Edith P. Mitchell(Thomas Jefferson University Hospital), Antoine Hollebecque(Institut Gustave Roussy), Mei Liu(Dana-Farber Cancer Institute), Abdel‐Baset Halim(Institut Gustave Roussy), Kunihiro Masuda(Tohoku University), Li‐Tzong Chen(National Health Research Institutes), Yaohua He(Dana-Farber Cancer Institute), Amit Mahipal(Dana-Farber Cancer Institute), Heung-Moon Chang(Ulsan College), Chigusa Morizane(Tokyo National Hospital)
New England Journal of Medicine
January 18, 2023
Cited by 530


Related Papers